Cytori Therapeutics’ Celution System for breast reconstruction may reduce or eliminate the practice of repeat procedures, leading to cost savings for the National Health Service (NHS) hospitals and breast cancer patients, according to the results from an economic analysis carried out by the UK NHS National Innovation Centre.
The analysis compared the cost and patient benefit resulting from Celution-based cell-enriched reconstruction with that of fat grafting, (lipomodelling).
NHS National Innovation Centre Technology and Product Innovation head Brian Winn said Cytori’s Celution System supplements a fat graft with a patient’s own adipose-derived regenerative cells to improve graft take and help regenerate damaged tissue.
"This minimally invasive treatment approach reduces or eliminate the practice of repeat procedures, leading to cost savings for the NHS," Winn said.
NHS Glasgow Royal Infirmary Hospital and the Nuffield Health Glasgow Hospital consultant plastic and reconstructive surgeon Eva Weiler-Mithoff said cell-enriched fat grafting is new technique in reconstructive surgery in particular for patients whose treatment by other techniques were not effective or available.
"The benefits of the technique are correction of contour defects after breast conservation surgery, but its most important contribution lies in soft tissue defects after radiotherapy or wounds that can be improved by the body’s own repair cells," Weiler-Mithoff said.